Key result
LDL induces a transient activation of p38MAPK in platelets, which is subsequently inhibited by LDL-induced activation of PECAM-1 and dephosphorylation via Ser/Thr phosphatases PP1/PP2A.
This study identifies PECAM-1 as a key negative regulator of LDL-induced platelet sensitization, acting through the dephosphorylation of p38MAPK.
Answers are grounded in this paper and cite their sources.
May inform platelet biology research; leaves open any clinical relevance of PECAM-1 in human LDL responses.
At physiological concentrations, low density lipoprotein (LDL) increases the sensitivity of platelets to aggregation- and secretion-inducing agents without acting as an independent activator of platelet functions. LDL sensitizes platelets by inducing a transient activation of p38MAPK, a Ser/Thr kinase that is activated by the simultaneous phosphorylation of Thr180 and Tyr182 and is an upstream regulator of cytosolic phospholipase A2 (cPLA2). A similar transient phosphorylation of p38MAPK is induced by a peptide mimicking amino acids 3359-3369 in apoB100 called the B-site. Here we report that the transient nature of p38MAPK activation is caused by platelet endothelial cell adhesion molecule 1 (PECAM-1), a receptor with an immunoreceptor tyrosine-based inhibitory motif. PECAM-1 activation by cross-linking induces tyrosine phosphorylation of PECAM-1 and a fall in phosphorylated p38MAPK and cPLA2. Interestingly, LDL and the B-site peptide also induce tyrosine phosphorylation of PECAM-1, and studies with immunoprecipitates indicate the involvement of c-Src. Inhibition of the Ser/Thr phosphatases PP1/PP2A (okadaic acid) makes the transient p38MAPK activation by LDL and the B-site peptide persistent. Inhibition of Tyr-phosphatases (vanadate) increases Tyr-phosphorylated PECAM-1 and blocks the activation of p38MAPK. Together, these findings suggest that, following a first phase in which LDL, through its B-site, phosphorylates and thereby activates p38MAPK, a second phase is initiated in which LDL activates PECAM-1 and induces dephosphorylation of p38MAPK via activation of the Ser/Thr phosphatases PP1/PP2A.
No takes yet. Share an insight, caveat, or question.
Relou et al. (2003) studied this question. Low density lipoprotein (LDL) and B-site peptide was evaluated on p38MAPK and cPLA2 phosphorylation and activation. LDL induces a transient activation of p38MAPK in platelets, which is subsequently inhibited by LDL-induced activation of PECAM-1 and dephosphorylation via Ser/Thr phosphatases PP1/PP2A.
Synapse has enriched 10 related papers. Consider them for comparative context: